Sorafenib in renal cell carcinoma

Critical Reviews in Oncology/Hematology

Volumn 80, Issue 2, 2011, Pages 314-322

  Arranz, José Ángel ^a   Climent, Miguel Ángel ^b   González Larriba, José Luis ^c   León, Luis ^d   Maroto, José Pablo ^e  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Efficacy; Renal cell carcinoma; Safety; Sequential treatment; Sorafenib; Tyrosine kinase inhibitor

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANGIOGENESIS INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERLEUKIN 2; LENALIDOMIDE; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

AGING; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; BRAIN DYSFUNCTION; BRAIN HEMORRHAGE; BRAIN METASTASIS; BRAIN TOXICITY; CANCER SURVIVAL; CARDIOTOXICITY; CLEAR CELL CARCINOMA; CROSS RESISTANCE; DESQUAMATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HEART FAILURE; HEMODIALYSIS; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; KARNOFSKY PERFORMANCE STATUS; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LOW DRUG DOSE; LYMPHOCYTOPENIA; METASTASIS POTENTIAL; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PROGNOSIS; PROGRESSION FREE SURVIVAL; PRURITUS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN TOXICITY; TUMOR VOLUME; URINARY EXCRETION; VOMITING; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; HUMANS; KIDNEY; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIDINES;

EID: 80053088777     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.01.008     Document Type: Review

References (55)

1. Cohen H., McGovern F. Renal cell carcinoma. N Engl J Med 2005, 353:3477-3490.
2. Rini B.I., Campbell S.C., Escudier B. Renal cell carcinoma. Lancet 2009, 373(9669):1119-1132.
3. Bellmunt J., Negrier S., Escudier B., et al. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG taskforce. Crit Rev Oncol Hematol 2009, 69:64-72.
4. Bellmunt J., Guix M. The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations. BJUI 2009, 103:572-577.
5. Escudier B., Szcylik C., Hutson T.E., et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:1280-1289.
6. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. JCO 2009, 27(22):3584-3590.
7. Rini B.L., Halabi S., Rosenberg J.E., et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. JCO 2008, 28(33):5422-5428.
8. Sablin M.P., Negrier S., Ravaud A., et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009, 182:29-34.
9. Bracarda S., De Simone V. Sequential therapies in metastatic renal cell carcinoma: option or strategy?. Eur Urol 2008, 54:1219-1222.
10. Bracarda S., Porta C., Boni C., et al. Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-α-2a (IFN) in metastatic renal cell carcinoma (MRCC) (RAPSODY): GOIRC study 0681. J Clin Oncol 2007, 25(18S):5100. [ASCO abstract 357].
11. Negrier S., Jager E., Porta C., et al. Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET. Med Oncol 2009, 12(September 12). [Epub ahead of print].
12. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
13. Stadler W.M., Figlin R.A., McDermott D.F., et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010, 116(5):1272-1280.
14. Beck J., Procopio I., Negrier S., et al. Final analysis of a large open-label, non-comparative, study of sorafenib in European patients with advanced RCC (EU-ARCCS). Eur J Cancer Suppl 2009, 7:434.
15. Henderson C.A., Bukowski R.M., Stadler W.M., et al. Sorafenib therapy in the management of advanced renal cell carcinoma with brain metastases: results from the ARCCS expanded access program. Eur Urol Suppl 2008, 7(3):245. Abstract 697.
16. Henderson C.A., Bukowski R.M., Stadler W.M., et al. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial: subset analysis of patients with brain metastasis. J Clin Oncol 2007, 25(18 Suppl.):15506.
17. Massard C., Zonierek J., Gross-Goupil M., et al. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol 2009, Epub October 22.
18. Ranze O., Hofman E., Distelrath A., et al. Renal cell cancer presented with leptomeningeal carcinomatosis effectively treated with sorafenib. Onkologie 2007, 30:450-451.
19. Valcamonico F., Ferrari V., Amoroso V., et al. Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma. J Neurooncol 2009, 91(1):47-50.
20. Miller A.A., Murry D.J., Owzar K., et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB60301. J Clin Oncol 2009, 27:1800-1805.
21. Smith W.B., Kipnes M.S., Marbury T.C., et al. Effects of renal impairment on the pharmacokinetics and safety of sorafenib. AACR meeting abstracts, April 2007 2007, p. 934.
22. Protzel C., Ruppinc S., Klebingat K., et al. Sorafenib for the treatment of metastatic renal cell carcinoma with chronic renal failure. Onkologie 2008, 31(Suppl. 1):PE591.
23. Maroto P., Sorafenib Tolerance in patients on chronic haemodialysis. Oncology 2008, 74:245-256.
24. Ruppin S., Protzel C., Klebingat K.J., et al. Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure. Eur Urol 2009, 55:986-988.
25. Sabbatini R., Porta C., Procopio G., et al. Use of tyrosine kinase inhibitors (TKI) in hemodialitic metastatic renal cell carcinoma patients. Eur Urol Suppl 2009, 8(4):185. Abstract, 258.
26. Hilger R.A., Richly H., Grubert M., et al. Pharmacokinetics of sorafenib in patients with renal impairment undergoing haemodialysis. In J Clin Pharmacol Ther 2009, 47:61-64.
27. Eisen T., Oudard S., Szcylik C., et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 2008, 100:1454-1463.
28. Simonelli C, Fratino L, Giacalone A, et al. Sorafenib in elderly cancer patients (ECP) with renal cell carcinoma (RCC): a single-institution experience. ASCO meeting. Abstract 382; 2008.
29. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24(18):2505-2512.
30. Hutson TE, Bellmunt J, Porto C, et al. Long-term safety with sorafenib in advanced RCC patients: data analysis from patients treated for over 1 year in TARGET trial for the sorafenib TARGET Clinical Trial Group. ASCO 2009 genitourinary cancers symposium. Abstract 326.
31. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27:3312-3318.
32. Herrmann E., Bierer S., Gerss J., et al. Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokine-refractory kidney cancer patients. Oncology 2008, 74:216-222.
33. Knox J.J., Figlin R.A., Stadler W.M., et al. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial in North America: safety and efficacy. J Clin Oncol 2007, 25(Suppl. 18). 5011.
34. Akaza H., Naito S., Tsukamoto T., et al. Efficacy and safety of long-term use of sorafenib: final report of a phase II trial of sorafenib in Japanese patients with unresectable/metastatic renal cell carcinoma. Joint 15th ECCO and 34th ESMO multidisciplinary congress in Berlin 2009, Poster 160.
35. García del Muro X., Maroto P., Mellado B., et al. Phase II trial of first-line sequential treatment with interleukin-2 plus interferon alfa followed by sorafenib in patients with advanced renal cell carcinoma. 33th ESMO congress in Stockholm 2008, Poster.
36. Dudek A.Z., Zolnierek J., Dham A., et al. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009, 115:61-67.
37. Eichelberg C., Heuer R., Chun F.K., et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 2008, 54(6):1373-1378.
38. Procopio G, Verzoni E, Guadalupi V, et al. Sequential use of sorafenib (So) followed by sunitinib (Su) in metastatic renal cell cancer (mRCC): a single-institution experience. ASCO 2009 genitourinary cancers symposium. Abstract 319.
39. Zimmerman K., Schmittel A., Steiner U., et al. Sunitinib treatment for patients with advanced clear-cell renal cell carcinoma after progression on sorafenib. Oncology 2009, 76:350-354.
40. Beck J., Bajetta E., Escudier B., et al. A large open-label, non-comparative, phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma. Eur J Cancer 2007, 5(Suppl. 4):4506.
41. Vickers M.M., Choueiri T.K., Rogers M., et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology 2010, (March 9). [Epub ahead of print].
42. Tamaskar I., García J.A., Elson P., et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008, 179:81-86.
43. Bhojani N., Jeldres C., Patard J.J., et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008, 53:917-930.
44. Gollob J.A., Rathmell K., Richmond T.M., et al. Phase II trial of sorafenib plus interferon Alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. Clin Oncol 2007, 25(22):3288-3295.
45. Wong M.K.K., Jarkowski A. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature. Pharmacotherapy 2009, 29(4):473-478.
46. Motzer R.J., Bacik J., Schwartz L.H., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004, 22:454-463.
47. Jager D., Ma J.H., Korbenfeld E., et al. 15th ECCO and 34th ESMO multidisciplinary congress, September 20-24, Berlin. PREDICT (patient characteristics in renal cell carcinoma and daily practice treatment with nexavar) global noninterventional study: first interim results 2009, 141. Poster.
48. Bukowski R., Cella D., Gondek K., et al. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 2007, 30(3):220-227.
49. Szczylik C, Cella D, Eisen T, et al. Comparison of kidney cancer symptoms and quality of life (QOL) in renal cell cancer (RCC) patients (pts) receiving sorafenib vs. interferon-α (IFN). 2008 ASCO annual meeting. Abstract 9603.
50. Bellmunt J., Eisen T., Fishman M., et al. Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol 2010 Apr 15, (Epub ahead of print).
51. Shuch B., Riggs S.B., LaRochelle J.C., et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJUI 2008, 102:692-696.
52. Di Silverio F., Sciarra A., Parente U., et al. Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. Urol Int 2008, 80:451-453.
53. Hakenberg O. Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. Urol Int 2008, 80:454.
54. Amin C., Wallen E., Pruthi R.S., et al. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology 2008, 72(4):864-868.
55. Cowey C.L., Amin C., Pruthi R.S., et al. Neoadjuvant clinical trial withsorafenib for patients with stage II or higher renal cell carcinoma. J. Clin. Oncol. 2010, 28(9):1502-1507.